Thomas Steyer’s Sutro Biopharma STRO Stock Holding History

Thomas Steyer’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-15,000	Closed	-$2.25M	–	103
2018 Q3	$2.25M	Buy	+15,000	New	+$2.27M	0.01%	100

Other funds holding STRO

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Thomas Steyer's STRO Position: Q4 2018 in Review

Thomas Steyer sold out of Sutro Biopharma (STRO) in Q4 2018, closing a stake of 15,000 shares — an estimated $2.25M sold.

Thomas Steyer first reported a position in STRO in Q3 2018 and held it in 1 quarter. The position peaked at $2.25M in Q3 2018. 43 funds tracked by Wall St. Rank hold STRO as of Q4 2018.

Thomas Steyer reported no remaining Sutro Biopharma position as of Q4 2018 after selling out during the quarter.
Thomas Steyer sold 15,000 Sutro Biopharma shares in Q4 2018, an estimated $2.25M.
Thomas Steyer first reported a position in Sutro Biopharma in Q3 2018 and held it in 1 quarter.
Thomas Steyer's Sutro Biopharma position peaked at $2.25M in Q3 2018.
43 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2018.

Based on Farallon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.